This is a great thread, thanks D and Worth.
The way I read the GSK reference, ATC is miles ahead...
Phase III vs Phase II proof of concept, 100+ vs 32 pts, clinical performance better, etc. Yet IDX899 has scored a deal - upfront payment of USD34m with more later - that sounds fantastic to suffering holders of AVX.
Could this mean Avexa is holding out for some super-deal?
Any thoughts?
CG
- Forums
- ASX - By Stock
- AVX
- valuation model
valuation model, page-4
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)